UV-A1 Phototherapy vs Clobetasol Propionate, 0.05%, in the Treatment of Vulvar Lichen Sclerosus A Randomized Clinical Trial
|
|
- Adele Park
- 5 years ago
- Views:
Transcription
1 Research Original Investigation UV-A1 Phototherapy vs Clobetasol Propionate,.5%, in the Treatment of Vulvar Lichen Sclerosus A Randomized Clinical Trial Sarah Terras, MD; Thilo Gambichler, MD; Rose K. C. Moritz, MD; Markus Stücker, MD; Alexander Kreuter, MD IMPORTANCE Topical corticosteroids are the current first-line therapy for vulvar lichen sclerosus (VLS). UV-A1 phototherapy may be a promising alternative treatment option, but controlled studies are lacking. OBJECTIVE To compare the efficacy of high-potent topical corticosteroids with UV-A1 phototherapy in the treatment of VLS. DESIGN, SETTING, AND PARTICIPANTS A 2-arm randomized clinical trial was conducted at a university hospital dermatology department according to the intention-to-treat principle with last observation carried forward. The study population comprised 3 female patients with VLS. INTERVENTIONS Treatment of VLS with clobetasol propionate,.5%, ointment applied once daily for 3 months or medium-dose UV-A1 (5 J/cm 2 ) home-based phototherapy, performed 4 times weekly for 3 months. MAIN OUTCOMES AND MEASURES Mean relative reduction of the total clinician s score (TCS) was considered the primary outcome measure. Secondary outcome measures included the reduction of pruritus and burning and/or pain according to a visual analog scale (VAS), a health-related quality of life score (Skindex-29), 2-MHz ultrasonography, and histopathological analysis before and after 3 months of therapy. RESULTS Fifteen patients were randomized in each treatment arm, and 2 patients dropped out in both treatment arms. After therapy, both therapies resulted in a significant decrease in mean TCS (51.4% [95% CI, 39.7% to 63.%] for clobetasol ointment [P <.1] and 35.6% [95% CI, 18.2% to 53.1%] for UV-A1 phototherapy [P =.6]). No significant difference was found between both treatments (P >.5). The Skindex-29 (mean difference [MD], 29.6 [95% CI, 7.9 to 51.2] [P =.9]) and the VAS score for pruritus (MD, 4.6 [95% CI, 1.5 to 7.7] [P =.5]) and burning and/or pain (MD, 4.2 [95% CI, 1.9 to 6.6] [P =.1]) significantly decreased after clobetasol treatment. After UV-A1 phototherapy, the VAS score for burning and/or pain (MD, 3.2 [95% CI,.7 to 5.7] [P =.1]) was also significantly reduced; however, there was no significant reduction in pruritus (MD, 2.1 [95% CI,.5 to 3.7] [P =.16]) and in the Skindex-29 score (MD, 4.9 [95% CI, 12.6 to 22.4] [P >.99]). A significant reduction of the corium thickness and a significant increase in dermal density in 2-MHz ultrasonography as well as significant histopathological reduction of the inflammatory infiltrate was observed after clobetasol treatment but not after UV-A1 phototherapy. CONCLUSIONS AND RELEVANCE Although resulting in a significant clinical improvement, UV-A1 phototherapy was inferior to the current gold standard treatment with topical high-potent corticosteroids with respect to practicability, relief of itch, and improvement in quality of life. UV-A1 phototherapy may be considered a potential second-line treatment for VLS. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT1422 JAMA Dermatol. 214;15(6): doi:1.11/jamadermatol Published online April 2, 214. Author Affiliations: Department of Dermatology, Venereology, and Allergology, Ruhr-University Bochum, Bochum, Germany. Corresponding Author: Alexander Kreuter, MD, Department of Dermatology, Venereology, and Allergology, Ruhr-University Bochum, Gudrunstrasse 56, Bochum, Germany (a.kreuter@derma.de). 621
2 Research Original Investigation UV-A1 vs Clobetasol in Vulvar Lichen Sclerosus Lichen sclerosus (LS) is a connective tissue disease that predominantly affects the anogenital area. An autoimmune background is likely, given the high association with other autoimmune diseases and the presence of highly specific antibodies targeting extracellular matrix protein-1. 1,2 Although vulvar lichen sclerosus (VLS) is relatively common and may have substantial psychological and emotional consequences, to date, only a few therapies have been evaluated in controlled studies. The gold standard of treatment for VLS consists of high-potent topical corticosteroids, such as clobetasol dipropionate applied once daily for 12 weeks. 3 Other therapeutic options include topical calcineurin inhibitors or, in severe and recalcitrant disease, surgery or cryotherapy. 3-5 UV-A1 phototherapy has been reported to be effective in the treatment of several sclerotic skin diseases including localized scleroderma and extragenital LS UV-A1 irradiation increases collagenase activity and suppresses collagen synthesis, resulting in a softening of former sclerotic skin lesions. 7 Moreover, UV-A irradiation has strong melanogenic properties, inducing a repigmentation of the hypopigmented lesions in LS. 7,9 Currently, only few data are available on UV-A1 phototherapy in VLS. The present controlled study was therefore initiated to compare the efficacy of UV-A1 phototherapy with topical high-potent corticosteroids, the current gold standard for VLS. Methods Study Design, Setting, and Participants The study protocol was approved by the ethics review board of Ruhr University Bochum (No ) and registered at ClinicalTrials.gov (NCT1422). All patients gave their written informed consent to participate in the study. This is an open 2-arm randomized clinical trial performed at a university hospital in Germany investigating UV-A1 phototherapy vs standard treatment (clobetasol propionate,.5%, ointment) in patients with VLS. From August 1, 21, to January 31, 212, 3 female patients older than 18 years were recruited from the outpatient clinic for connective tissue diseases of the Department of Dermatology, Venereology, and Allergology at Ruhr University Bochum. Inclusion criteria were (1) active, histopathologically confirmed LS causing symptoms such as itch, burning, or pain present for less than 2 years and (2) age 18 years or older at study inclusion. If patients were treated with topical corticosteroids before initiation of the study, a washout period of 4 weeks was required. Exclusion criteria were (1) age younger than 18 years at study inclusion; (2) history of photoallergic reactions; (3) known genodermatoses with sensibility to UV light; (4) history of skin cancer; (5) notable sun exposure 3 months before inclusion; or (6) phototherapy in the last 4 weeks before study inclusion or planned phototherapy in the next 9 months. Randomization and Allocation to Treatment The randomization was performed using a random allocation software as described previously. 12 A total of 51 patients with genital lichen sclerosus were assessed for eligibility in this study. Among those, 21 patients were excluded because they did not meet the inclusion criteria or refused to participate. Thirty patients were randomized, 15 to each of the 2 treatment arms (UV-A1 phototherapy or topical high-potent corticosteroid). Of these 3 patients, 26 were included in the final analysis (Figure 1). Primary Outcome Measures Clinical examinations during the treatment and follow-up period were performed at day (T or baseline), after 1 month (T1), after 2 months (T2), after 3 months (T3, end of therapy), and at follow-up 3 months after the end of therapy. Photographic documentation was performed at each visit. Lesional skin biopsies were performed at baseline and after 3 months of therapy. Because there is currently no validated clinical score available for VLS, clinical assessment of efficacy was performed using our own score, the total clinician s score (TCS). In this score, hypopigmentation, sclerosis, atrophy, hyperkeratosis, erosions, edema, and erythema are each assigned a value from to 3, with indicating absent ; 1, slight ; 2, moderate ; and 3, severe. The total of these values was considered the TCS, with a maximum score of 21. The primary outcome measure was the mean reduction in TCS at T3 (after 3 months of treatment). The observer determining the TCS could not be blinded because of lesional tanning after UV-A1 phototherapy. Secondary Outcome Measures Secondary outcome measures were patients scores evaluating pruritus and burning and/or pain and the Skindex-29 score at T3. Pruritus and burning and/or pain were evaluated at each clinical visit by means of a visual analog scale (VAS) score on a 1-point scale, with indicating no sensation and 1, maximum intensity of sensation. The Skindex-29 is a validated Figure 1. Flow Diagram of the Study 15 Assigned to receive clobetasol propionate,.5% 14 Received intervention as assigned 1 Did not receive intervention as assigned (no histological confirmed lichen sclerosus) 1 Lost to follow-up (patient no longer wanted to cooperate in a clinical trial) Discontinued intervention 13 Included in analysis Excluded from analysis 51 Assessed for eligibility 3 Randomized 21 Excluded 9 Did not meet inclusion criteria 12 Refused to participate Other reasons 15 Assigned to receive UV-A1 14 Received intervention as assigned 1 Did not receive intervention as assigned (experienced severe skin infection before initiation of UV-A1 phototherapy) Lost to follow-up 1 Discontinued intervention (1 received systemic immunosuppressants for another autoimmune disease) 13 Included in analysis Excluded from analysis 622 JAMA Dermatology June 214 Volume 15, Number 6 jamadermatology.com
3 UV-A1 vs Clobetasol in Vulvar Lichen Sclerosus Original Investigation Research questionnaire in the German language to measure the healthrelated quality of life. 13 Additional secondary outcome measures included the increase of dermal density and reduction of dermal thickness (corium thickness in micrometers), as measured by 2-MHz sonography (DUB 2; taberna pro medicum), as well as the reduction of lesional lymphocytic infiltrates in hematoxylin-eosin stained samples as measured semiquantitatively (, no lymphocytes; 1, slight lymphocytic infiltrate; 2, moderate lymphocytic infiltrate; and 3, strong lymphocytic infiltrate) before and after treatment. The examination of the ultrasonographic images and histological specimens was performed by a blinded observer (M.S.). Figure 2. Portable UV-A1 Sellas Irradiation Unit (System Dr Sellmeier) Used in This Study Interventions UV-A1 phototherapy was performed with a specially designed Sellas irradiation unit (System Dr Sellmeier) emitting wavelengths mainly from 34 to 4 nm. All patients received a portable irradiation unit to take home and performed the radiation therapy in a comfortable environment at a suitable time for the patients. An example of this UV-A1 irradiation device (the so-called vulva lamp) is shown in Figure 2. Irradiation intensity at body distance was 24 mw/cm 2. The distance between the irradiation unit and the irradiated genital area was approximately 25 cm. The UV-A1 doses were intensified during the first 5 treatment sessions. In the first session, a dose of 1 J/cm 2 was used, resulting in a irradiation time of approximately 5 minutes. In the following 4 sessions, the radiation energy was successively increased to 2 J/cm 2 (irradiation time approximately 1 minutes), 3 J/cm 2 (irradiation time approximately 16 minutes), 4 J/cm 2 (irradiation time approximately 22 minutes), and 5 J/cm 2 (irradiation time approximately 27 minutes), respectively. From the fifth session until the end of the treatment period, 5-J/cm 2 UV-A1 was applied, resulting in a medium-dose UV-A1 phototherapy. 14 UV-A1 phototherapy was administered 4 times per week for a total of 12 weeks, resulting in 48 irradiations in total. Additional therapy was restricted to the use of emollients. Emollients were not applied shortly (within 6 minutes) before phototherapy. The comparative intervention was the use of topical high-potent corticosteroids. Clobetasol propionate,.5%, in white vaseline was applied once daily, preferably before bedtime, for 12 weeks. Sample Size Calculation The null hypothesis was based on the assumption that there is no significant difference of efficacy between UV-A1 phototherapy and clobetasol propionate,.5%, ointment in the treatment of VLS. On the basis of an expected mean difference (MD) of 6.1 points in TCS (difference of mean relative TCS reduction of 33%) and a statistical power of 8% at the 5% α level, at least 26 patients were needed in this study, excluding a dropout rate of approximately 2%. 15 Statistical Analysis Data analysis was performed using the statistical package Med- Calc Software. The primary outcome was analyzed on an intention-to-treat basis using baseline TCSs and last available TCSs of all randomized patients. 16 Analysis of data distribution was assessed by the D Agostino-Peason test. Means, standard All patients randomized to UV-A1 phototherapy received a portable irradiation unit to take home in order to perform the radiation therapy in a comfortable environment. errors, and 95% confidence intervals were calculated. Repeated measures analysis of variance including Bonferroni correction was used to detect significant differences of parameters assessed at baseline, at T3, and at follow-up. 17 Primary and secondary outcome measures evaluated at T3 were analyzed using the F test, followed by the independent 2-sided t test (assuming equal variances) or Welch test (assuming unequal variances). Statistical significance was set at the 5% α level (2-sided). Results A total of 3 patients were enrolled in the study, 15 in each of the 2 study arms. The median age was 6.3 years (range, 2-81 years). A flow diagram of patient treatment, including reasons for discontinuation, is shown in Figure 1. Of the 3 patients, 1 patient was excluded because the clinical diagnosis of VLS could not be histopathologically confirmed. One patient was excluded from the study because during the treatment phase, a systemic immunosuppressive therapy was initiated to treat another autoimmune disease. One patient dropped out of the study because of an acute bacterial skin infection in the genital area before initiation of the UV-A1 irradiation sessions. One patient was lost to follow-up. At baseline, both groups did not show any differences in any of the primary and secondary outcome measures (P >.5). Primary Outcome A summary of the results is detailed in the Table. After 3 months of treatment, both therapies resulted in a significant decrease in mean TCS (51.4% [95% CI, 39.7% to 63.%] for clobetasol ointment [P <.1] and 35.6% [95% CI, 18.2% to 53.1%] for UV-A1 phototherapy [P =.6]) (Figure 3). No significant difference in the relative reduction of the TCS was found be- jamadermatology.com JAMA Dermatology June 214 Volume 15, Number 6 623
4 Research Original Investigation UV-A1 vs Clobetasol in Vulvar Lichen Sclerosus Table. Summary of the Results of the Primary and Secondary Outcome Measures Before and After Treatment With UV-A1 Phototherapy and Topical High-Potent Corticosteroids Outcome Measure TCS score 9.5 (7.7 to 11.1) VAS score for itching VAS score for burning and/or pain Skindex-29 score Infiltrate (histologically) CT 2-MHz sonography DD 2-MHz sonography Clobetasol Propionate,.5% UV-A1 Phototherapy Mean (95% CI) P Value Mean (95% CI) T T3 MD for MD T T3 MD 6.2 (4.2 to 8.2) 5.2 (3.1 to 7.2) 85.8 (77.1 to 94.6) 2.4 (2. to 2.8) 4.5 (3.1 to 5.7) 1.6 (.4 to 3.6).9 ( to 2.5) 56.3 (37. to 75.5) 1.5 (1.1 to 1.9) (2613 to 3842) (274 to 287) 27.2 (2.7 to 33.8) 42.5 (33.8 to 51.2) 5. (2.7 to 7.4) 4.6 (1.5 to 7.7) 4.2 (1.9 to 6.6) 29.6 (7.9 to 51.2).9 (.2 to 1.7) 786 ( 235 to 338) 15. (8. to 22.) < (9.5 to 14.9) (4.1 to 8.8) (5. to 8.1) (76.8 to 95.6) (1.7 to 2.6) (2739 to 4368) < (19.7 to 37.9) 7.6 (4.5 to 1.8) 4.6 (1.6 to 7.6) 3.4 (1.8 to 4.9) 8.6 (71.7 to 9.8) 2. (1.6 to 2.4) 3272 (2641 to 393) 28.7 (17.3 to 4.1) 4.5 (1.4 to 7.7) 2.1 (.5 to 3.7) 3.2 (.7 to 5.7) 4.9 ( 12.6 to 22.4).2 (.4 to.7) 282 ( 136 to 473).1 ( 6.9 to 6.7) P Value for MD Difference, UV-A1 vs Clobetasol Propionate,.5% MD P Value for MD.6.5 > < <.5 > < < < <.5 Abbreviations: CT, corium thickness; DD, dermal density; MD, mean difference; T, baseline; T3, after 3 months of therapy; TCS, total clinician s score. tween both treatments (P >.5; MD, 15.7% [95% CI, 35.2% to 3.7%]). Representative clinical pictures before and after both therapies are depicted in Figure 4. Secondary Outcome After treatment with clobetasol ointment, the VAS score significantly decreased for pruritus (MD, 4.6 [95% CI, 1.5 to 7.7] [P =.5]) and burning and/or pain (MD, 4.2 [95% CI, 1.9 to 6.6] [P =.1]), and also the Skindex-29 score significantly decreased (MD, 29.6 [95% CI, 7.9 to 51.2] [P =.9]). After UV-A1 phototherapy, the VAS score for burning and/or pain (MD, 3.2 [95% CI,.7 to 5.7][P =.1]) reduced significantly; however, there was no significant reduction in pruritus (MD, 2.1 [95% CI,.5 to 3.7][P =.16]) and Skindex-29 score (MD, 4.9 [95% CI, 12.6 to 22.4] [P >.99]; Figure 3). Three months after the end of the therapy, all primary and secondary outcome points returned to the baseline level, before initiation of the treatment. The clinical improvement seen at T3 was confirmed by 2- MHz ultrasonography. Corium thickness was relatively high before therapy and significantly decreased into normal ranges after topical clobetasol therapy (MD, 786 [95% CI, 235 to 338] [P =.3]). There was also a statistically significant increase of dermal density after clobetasol treatment (MD, 15. [95% CI, 8. to 22.] [P <.1]), correlating with a reduction of the edema. After treatment with UV-A1 phototherapy, a reduction of corium thickness and increase in dermal density could also be observed; however, it did not reach statistical significance (MD, 282 [95% CI, 136 to 473] [P =.41], and MD,.1 [95% CI, 6.9 to 6.7] [P =.97], respectively). In the histopathological evaluation of the lesional skin biopsy specimens before and after therapy, a significant reduction of lymphocytic infiltrates after topical corticosteroid therapy was observed (MD,.9 [95% CI,.2 to 1.7] [P =.2]), whereas after UV-A1 phototherapy, no significant reduction of lymphocytic infiltrates was seen (MD,.2 [.4 to.7] [P =.51]). Tolerability The predominantly reported short-term adverse effects of UV-A1 phototherapy include erythema, pruritus, xerosis cutis, and tanning. 8 Patients treated with UV-A1 phototherapy in this study initially reported an increase of pruritus. We advised our patients to apply white vaseline directly (within 3 minutes) after the radiation session to prevent dehydration of the skin, which led to a marked subjective improvement. In total, there was only a slight, nonsignificant reduction of pruritus (P =.16) after 3 months of treatment with UV-A1 phototherapy. After UV-A1 treatment, a marked hyperpigmentation in the anogenital area was seen in all cases. However, this was not considered as a disturbing adverse effect by the patients. No erythema or sunburn following UV-A1 phototherapy was reported. Discussion According to the British Association of Dermatologists guidelines for the management of LS, the first-line treatment for VLS is the use of topical high-potent corticosteroids. 18 In this context, clobetasol propionate,.5%, cream is currently considered the gold standard, leading to a substantial decrease of inflammation and clinical symptoms. 3 After therapy with highpotent corticosteroids, approximately 6% of patients experience a complete remission of their symptoms, resulting in a resolution of ecchymoses, fissures, erosions, and hyperkeratoses. 19,2 Thus, the use of clobetasol propionate is safe and effective in VLS, and there is yet no evidence of notable steroid-related damage following its appropriate use. 18 However, skin atrophy, scarring, and hypopigmentation are irreversible in VLS. UV-A1 phototherapy was previously shown to be effective in a variety of sclerotic skin diseases including localized scleroderma, systemic sclerosis, eosinophilic fasciitis, necro- 624 JAMA Dermatology June 214 Volume 15, Number 6 jamadermatology.com
5 UV-A1 vs Clobetasol in Vulvar Lichen Sclerosus Original Investigation Research Figure 3. Outcome Measures Used in This Study A B TCS 8 Skindex Clobetasol propionate,.5% UV-A1 2 C D VAS Burning/Pain 6 4 VAS Itching A, Total clinician s score (TCS) by visit. B, Mean Skindex-29 scores by visit. C, Mean visual analog (VAS) scores for burning and/or pain by visit. D, Mean VAS scores for itching by visit. T indicates baseline; T1, after 1 month of therapy; T2, after 2 months of therapy; T3, at end of therapy; and F3, 3 months after the end of therapy. Error bars indicate the standard error of the mean. biosis lipoidica, chronic sclerodermic graft-vs-host disease, and scleroderma adultorum. 6,7,21-25 UV-A1 phototherapy is generally divided into the following 3 dosages: low-dose UV-A1 (1-2 J/cm 2 ), medium-dose UV-A1 (2-7 J/cm 2 ), and high-dose UV-A1 (7-13 J/cm 2 ). 14 The treatment of extragenital LS with lowdose UV-A1 was first reported by our study group in 21. 1,11 In a small prospective uncontrolled trial, 7 we later treated 1 patients with extragenital LS using low-dose UV-A1 phototherapy (2 J/cm 2 ; cumulative dose of 8 J/cm 2 ). Low-dose UV-A1 phototherapy resulted in a marked reduction of the clinical score and a statistically significant decrease of ultrasonographically measured skin thickness as well as a statistically significant increase of dermal density. Most patients reported a remarkable softening and repigmentation of the affected skin. 7 Rombold et al 26 later confirmed the good response of extragenital LS lesions using medium-dose UV-A1 phototherapy. The exact mechanism of action of UV-A1 phototherapy in sclerotic skin diseases is not fully understood. 27 In general, UV-A1 phototherapy influences both lesional fibroblasts and inflammatory cells. UV-A1 irradiation leads to an increased collagenase production in fibroblasts with up-regulation of metalloproteinases, partly due to the increased production of hydrogen peroxide, as well as an up-regulation of α-melanocyte stimulating hormone. 28,29 UV-A1 phototherapy induces a down-regulation of interleukins 6 and 8, both cytokines that play a pivotal role in collagen metabolism. 3 Moreover, UV-A1 phototherapy influences the expression of SMAD-7, a major inhibitory regulator of the key-fibrogenic cytokine tissue growth factor-β, and increases the expression of interferon-γ, an antifibrotic cytokine To our knowledge, UV-A1 phototherapy in VLS has only been reported once in a small case series of patients. 34 In this study, 7 women with severe and progressive VLS not responding to ultrapotent topical corticosteroids were included. UV-A1 therapy led to a moderate improvement in 3 and to a minimal improvement in 2 of the 7 patients. The present study was the first randomized clinical trial to assess the effectiveness and safety of UV-A1 phototherapy in the treatment of VLS. Moreover, it is one of the few controlled studies that have so far been conducted in LS. In general, we could confirm the high efficacy of clobetasol propio- jamadermatology.com JAMA Dermatology June 214 Volume 15, Number 6 625
6 Research Original Investigation UV-A1 vs Clobetasol in Vulvar Lichen Sclerosus Figure 4. Treatment of Vulvar Lichen Sclerosus With Topical Clobetasol Propionate,.5%, Ointment and UV-A1 Phototherapy A C A, Extensive genital lichen sclerosus. B, Significant clinical improvement with complete clearance of all erosions and fissures following topical treatment with clobetasol ointment. C, Widespread genital lichen sclerosus. D, Marked clinical improvement with clearance of perilesional erythema and reduction of hyperkeratoses and erosions. The clinical pictures are representative of the outcome of the study, showing a significant improvement following therapy with clobetasol ointment (A and B) and UV-A1 phototherapy (C and D). B D nate,.5%, in VLS. On the basis of our results and those of others, topical corticosteroids should be considered the firstline approach for VLS. 3,18 However, we also demonstrated that UV-A1 phototherapy is an effective and well-tolerated treatment for VLS as well. Although in this study UV-A1 phototherapy was not as effective as the gold standard therapy with high-potent corticosteroids, it resulted in a significant clinical improvement and reduction of burning and/or pain. Moreover, UV-A1 phototherapy was well tolerated, easy to deliver, and could be performed by the patient herself at an appropriate time and in a comfortable environment. Therefore, UV-A1 phototherapy can be considered as an alternative therapeutic option in the treatment of genital LS. During follow-up, the primary and secondary end points in both therapies returned to the level before initiation of the therapy. This means that both treatments only transiently suppress the activity of disease. It also underlines the necessity to develop a long-term concept for treatment of VLS. Recently, it was published that once VLS has been stabilized with topical corticosteroids, the twice-weekly proactive application of mometasone furoate,.1%, ointment over 56 weeks was an effective and safe therapy option in maintaining VLS remission and in preventing the occurrence of relapse. 35 Patients with VLS have an increased risk of developing squamous cell carcinoma (SCC). Although the overall risk for malignant transformation of VLS is low (<5% of all VLS cases), they should be regularly monitored for malignant transformation. 18,36 UV irradiation has a major role in the pathogenesis of SCC because of its capacity to induce immunosuppression and DNA damage. However, in contrast to UV-B, UV-A1 irradiation in cell cultures neither induced measurable DNA damage nor induced cell death in the doses up to 15 J/cm Other studies, however, showed that the basal layer is more vulnerable to the carcinogenic effects of UV-A1 than would be predicted by mouse models. 38 Sage et al 39 recently discussed in detail the controversial data on the UV-A induced mutational events obtained for various types of eukaryotic cells, including human skin cells. In the present study, no cases of SCC or precursor lesions occurred, but the follow-up period was very short. Accordingly, long-term follow-up has to be performed in these patients to assess the risk of SCC development following UV-A1 phototherapy in VLS. In accordance with Beattie et al, 34 we think that UV-A1 phototherapy may have an acceptable risk-benefit ratio for the treatment of VLS. Nevertheless, more research is needed in the field of UV-A1 induced immunosuppression and carcinogenesis. 39,4 The results reported herein should be viewed in light of the limitations of the study. The sample size calculation was based on a large effect size (mean difference between treatments). The 95% confidence interval of differences regarding the relative reduction of TCS was wide, indicating that the sample size was too small to detect smaller but still clinically meaningful differences between the 2 treatments assessed. Moreover, the observer determining the clinical response could not be blinded owing to the marked tanning after UV-A1 phototherapy, and this might have influenced the outcome of the study. Finally, the follow-up was relatively short given that chronic UV damage takes a relatively long period. These effects will be evaluated in a future long-term follow-up study. Conclusions Both topical high-potent corticosteroids and UV-A1 phototherapy significantly improved VLS. However, UV-A1 was inferior with respect to practicability, relief of itch, and improvement in quality of life. Therefore, high-potent corticosteroids remain the first-line treatment for VLS. Nevertheless, UV-A1 phototherapy may be considered an alternative second-line treatment option. ARTICLE INFORMATION Accepted for Publication: August 22, 213. Published Online: April 2, 214. doi:1.11/jamadermatol Author Contributions: Drs Terras and Kreuter had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Terras, Gambichler, Moritz, Kreuter. Acquisition of data: Terras, Stücker, Kreuter. Analysis and interpretation of data: Terras, Gambichler, Stücker, Kreuter. Drafting of the manuscript: Terras, Kreuter. Critical revision of the manuscript for important intellectual content: Terras, Gambichler, Moritz, Stücker, Kreuter. Statistical analysis: Gambichler. Administrative, technical, and material support: Terras, Moritz, Stücker. Study supervision: Gambichler, Kreuter. 626 JAMA Dermatology June 214 Volume 15, Number 6 jamadermatology.com
7 UV-A1 vs Clobetasol in Vulvar Lichen Sclerosus Original Investigation Research Conflict of Interest Disclosures: None reported. Funding/Support: FoRUM (Forschungsförderung Ruhr University Bochum Medizinische Fakultat, project F615-28) funded this work. Role of the Sponsor: The sponsor had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Additional Contributions: Kim Allrich and Marina Skrygan, PhD, Department of Dermatology, Ruhr-University Bochum, provided technical assistance. They did not receive compensation for their contributions. REFERENCES 1. Kreuter A, Wischnewski J, Terras S, Altmeyer P, Stücker M, Gambichler T. Coexistence of lichen sclerosus and morphea: a retrospective analysis of 472 patients with localized scleroderma from a German tertiary referral center. J Am Acad Dermatol. 212;67(6): Oyama N, Chan I, Neill SM, et al. Autoantibodies to extracellular matrix protein 1 in lichen sclerosus. Lancet. 23;362(9378): Goldstein AT, Creasey A, Pfau R, Phillips D, Burrows LJ. A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosus. J Am Acad Dermatol. 211;64(6):e99-e Goldstein AT, Marinoff SC, Christopher K. Pimecrolimus for the treatment of vulvar lichen sclerosus: a report of 4 cases. J Reprod Med. 24; 49(1): Kastner U, Altmeyer P. Cryosurgery the last resort or a surgical alternative in the treatment of lichen sclerosus et atrophicus of the vulva (LSAV)? [in German]. J Dtsch Dermatol Ges. 23;1(3): Fett N, Werth VP. Update on morphea, part II: outcome measures and treatment. J Am Acad Dermatol. 211;64(2): Kreuter A, Gambichler T, Avermaete A, et al. Low-dose ultraviolet A1 phototherapy for extragenital lichen sclerosus: results of a preliminary study. J Am Acad Dermatol. 22;46 (2): Kroft EB, Berkhof NJ, van de Kerkhof PC, Gerritsen RM, de Jong EM. Ultraviolet A phototherapy for sclerotic skin diseases: a systematic review. J Am Acad Dermatol. 28;59 (6): Ravnbak MH, Wulf HC. Pigmentation after single and multiple UV-exposures depending on UV-spectrum. Arch Dermatol Res. 27;299(1): Kreuter A, Jansen T, Stücker M, et al. Low-dose ultraviolet-a1 phototherapy for lichen sclerosus et atrophicus.clin Exp Dermatol. 21;26(1): Kreuter A, von Kobyletzki G, Happe M, et al. Ultraviolet-A1 (UVA1) phototherapy in lichen sclerosus et atrophicus [in German]. Hautarzt. 21;52(1): Saghaei M. Random allocation software for parallel group randomized trials. BMC Med Res Methodol. 24;4: Augustin M, Wenninger K, Amon U, et al. German adaptation of the Skindex-29 questionnaire on quality of life in dermatology. Dermatology. 24;29(1): Gambichler T, Terras S, Kreuter A. Treatment regimens, protocols, dosage, and indications for UVA1 phototherapy: facts and controversies. Clin Dermatol. 213;31(4): Moher D, Dulberg CS, Wells GA. Statistical power, sample size, and their reporting in randomized controlled trials. JAMA. 1994;272(2): Heritier SR, Gebski VJ, Keech AC. Inclusion of patients in clinical trial analysis. Med J Aust.23; 179(8): Altman DG, Bland JM. Comparing several groups using analysis of variance. BMJ.1996;312 (744): Neill SM, Lewis FM, Tatnall FM, Cox NH; British Association of Dermatologists. British Association of Dermatologists guidelines for the management of lichen sclerosus 21. Br J Dermatol.21;163 (4): Cooper SM, Gao XH, Powell JJ, Wojnarowska F. Does treatment of vulvar lichen sclerosus influence its prognosis? Arch Dermatol.24;14(6): Renaud-Vilmer C, Cavelier-Balloy B, Porcher R, Dubertret L. Vulvar lichen sclerosus: effect of long-term topical application of a potent steroid on the course of the disease. Arch Dermatol. 24;14 (6): Weber HO, Schaller M, Metzler G, Röcken M, Berneburg M. Eosinophilic fasciitis and combined UVA1 retinoid corticosteroid treatment. Acta Derm Venereol. 28;88(3): Beattie PE, Dawe RS, Ibbotson SH, Ferguson J. UVA1 phototherapy for treatment of necrobiosis lipoidica. Clin Exp Dermatol. 26;31(2): Grundmann-Kollmann M, Behrens S, Gruss C, Gottlöber P, Peter RU, Kerscher M. Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy. J Am Acad Dermatol. 2;42(1, pt 1): Ständer H, Schiller M, Schwarz T. UVA1 therapy for sclerodermic graft-versus-host disease of the skin. J Am Acad Dermatol. 22;46(5): Eberlein-König B, Vogel M, Katzer K, et al. Successful UVA1 phototherapy in a patient with scleredema adultorum. J Eur Acad Dermatol Venereol. 25;19(2): Rombold S, Lobisch K, Katzer K, Grazziotin TC, Ring J, Eberlein B. Efficacy of UVA1 phototherapy in 23 patients with various skin diseases. Photodermatol Photoimmunol Photomed. 28;24 (1): Kreuter A, Breuckmann F, Uhle A, et al. Low-dose UVA1 phototherapy in systemic sclerosis. J Am Acad Dermatol. 24;5(5): Brenneisen P, Briviba K, Wlaschek M, Wenk J, Scharffetter-Kochanek K. Hydrogen peroxide (H2O2) increases the steady-state mrna levels of collagenase/mmp-1 in human dermal fibroblasts. Free Radic Biol Med. 1997;22(3): Kiss M, Wlaschek M, Brenneisen P, et al. Alpha-melanocyte stimulating hormone induces collagenase/matrix metalloproteinase-1 in human dermal fibroblasts. Biol Chem Hoppe Seyler. 1995; 376(7): Kreuter A, Hyun J, Skrygan M, et al. Ultraviolet A1-induced downregulation of human beta-defensins and interleukin-6 and interleukin-8 correlates with clinical improvement in localized scleroderma.br J Dermatol. 26;155(3): Edwards DR, Murphy G, Reynolds JJ, et al. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J. 1987;6(7): Gambichler T, Tomi NS, Skrygan M, Altmeyer P, Kreuter A. Alterations of TGF-beta/Smad mrna expression in atopic dermatitis following narrow-band ultraviolet B phototherapy: results of a pilot study. J Dermatol Sci. 26;44(1): El-Mofty M, Mostafa W, Esmat S, et al. Suggested mechanisms of action of UVA phototherapy in morphea: a molecular study. Photodermatol Photoimmunol Photomed. 24;2 (2): Beattie PE, Dawe RS, Ferguson J, Ibbotson SH. UVA1 phototherapy for genital lichen sclerosus. Clin Exp Dermatol. 26;31(3): Virgili A, Minghetti S, Borghi A, Corazza M. Proactive maintenance therapy with a topical corticosteroid for vulvar lichen sclerosus: preliminary results of a randomized study. Br J Dermatol. 213;168(6): Abramov Y, Elchalal U, Abramov D, Goldfarb A, Schenker JG. Surgical treatment of vulvar lichen sclerosus: a review. Obstet Gynecol Surv. 1996;51 (3): Lisby S, Gniadecki R, Wulf HC. UV-induced DNA damage in human keratinocytes. Exp Dermatol. 25;14(5): Tewari A, Grage MM, Harrison GI, Sarkany R, Young AR. UVA1 is skin deep. Photochem Photobiol Sci. 213;12(1): Sage E, Girard PM, Francesconi S. Unravelling UVA-induced mutagenesis. Photochem Photobiol Sci. 212;11(1): Schwarz T, Schwarz A. Molecular mechanisms of ultraviolet radiation-induced immunosuppression. EurJCellBiol. 211;9(6-7): jamadermatology.com JAMA Dermatology June 214 Volume 15, Number 6 627
Clearance in vulvar lichen sclerosus: a realistic treatment endpoint or a chimera?
DOI: 10.1111/jdv.14516 JEADV SHORT REPORT Clearance in vulvar lichen sclerosus: a realistic treatment endpoint or a chimera? A. Borghi,* A. Virgili, S. Minghetti, G. Toni, M. Corazza Dipartimento di Scienze
More informationSTUDY. 1% Pimecrolimus, 0.005% Calcipotriol, and 0.1% Betamethasone in the Treatment of Intertriginous Psoriasis
STUDY 1% Pimecrolimus, 0.005% Calcipotriol, and 0.1% Betamethasone in the Treatment of Intertriginous Psoriasis A Double-blind, Randomized Controlled Study Alexander Kreuter, MD; Anna Sommer, MD; Julia
More informationIn former years, patients were treated with broad-band
ORIGINAL ARTICLE Efficacy of UVA1 phototherapy in 23 patients with various skin diseases S. Rombold, K. Lobisch, K. Katzer, T. C. Grazziotin, J. Ring & B. Eberlein Department of Dermatology and Allergy
More informationComparison of the narrow band UVB versus systemic corticosteroids in the treatment of lichen planus: A randomized clinical trial
Received: 10.7.2011 Accepted: 5.12.2011 Original Article Comparison of the narrow band UVB versus systemic corticosteroids in the treatment of lichen planus: A randomized clinical trial Fariba Iraji, 1
More informationAcitretin for Severe Lichen Sclerosus of Male Genitalia: A Randomized, Placebo Controlled Study
Acitretin for Severe Lichen Sclerosus of Male Genitalia: A Randomized, Placebo Controlled Study D. Ioannides, E. Lazaridou,* Z. Apalla, E. Sotiriou, S. Gregoriou and D. Rigopoulos From the First Department
More informationLichen sclerosus. Lichen planus
Lichen sclerosus Lichen planus Dr Fiona Lewis, Consultant Dermatologist, Heatherwood and Wexham Park NHS Foundation Trust & St John s Institute of Dermatology, GSTT Outline Typical features of lichen sclerosus
More informationWHITE PAPER SmartXide 2 V 2 LR. MonaLisa Touch Dual Probe Therapy for the Treatment of Lichen Sclerosus and Vaginal Atrophy
WHITE PAPER SmartXide 2 V 2 LR MonaLisa Touch Dual Probe Therapy for the Treatment of Lichen Sclerosus and Vaginal Atrophy DEKA White Paper SMARTXIDE 2 V 2 LR November 2015 MonaLisa Touch Dual Probe Therapy
More informationAsymptomatic Undiagnosed Lichen Sclerosus
Asymptomatic Undiagnosed Lichen Sclerosus Lynette J. Margesson MD FRCPC Assistant Professor of Obstetrics & Gynecology and Surgery(Dermatology) Geisel School of Medicine at Dartmouth Lebanon, NH, USA Disclosures
More informationOriginal Policy Date
MP 2.01.58 Light Therapy for Vitiligo Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Created with literature search/12:2013 Return to Medical Policy
More informationNarrow-band UVB PHOTOTHERAPY for Skin Diseases
Narrow-band UVB PHOTOTHERAPY for Skin Diseases By Dr. Manal Bosseila Cairo University, Egypt HISTORICAL ASPECT In 1978: Irradiation cabin with broad band UVB tubes was introduced for psoriasis & uremic
More informationExperience with UVA1 phototherapy in treatment of skin diseases in Kuwait
ORIGINAL ARTICLE Experience with UVA1 phototherapy in treatment of skin diseases in Kuwait Hanan Boabbas, PhD, Jihan Rajy, MD, Haneen Alraqim, PhD As ad Al-Hamad Dermatology Center, Sabah Hospital, Kuwait
More informationAtopic dermatitis (AD) is a common chronic skin. Phototherapy in the management of atopic dermatitis: a systematic review.
Photodermatol Photoimmunol Photomed 2007; 23: 106 112 Blackwell Munksgaard r 2007 The Authors Journal compilation r 2007 Blackwell Munksgaard Review article Phototherapy in the management of atopic dermatitis:
More informationDermal sclerosis is a manifestation of many skin
Photodermatol Photoimmunol Photomed 2005; 21: 157 165 Blackwell Munksgaard Copyright r Blackwell Munksgaard 2005 Review article Phototherapy and photochemotherapy of sclerosing skin diseases Michaela Brenner,
More informationUltraviolet A1 phototherapy: a British Photodermatology Group workshop report
Clinical dermatology Review article CED Clinical and Experimental Dermatology CPD Ultraviolet A1 phototherapy: a British Photodermatology Group workshop report A. C. Kerr, J. Ferguson, S. K. Attili, P.
More informationThis PDF is available for free download from a site hosted by Medknow Publications
Net Study Comparison of clinical efficacy of topical tazarotene.1% cream with topical clobetasol propionate.5% cream in chronic plaque psoriasis: A double-blind, randomized, right-left comparison study
More informationScottish Medicines Consortium
Scottish Medicines Consortium imiquimod 5% cream (Aldara) No. (385/07) Meda Pharmaceuticals Ltd 04 April 2008 The Scottish Medicines Consortium has completed its assessment of the above product and advises
More informationSTUDY. Pulsed High-Dose Corticosteroids Combined With Low-Dose Methotrexate in Severe Localized Scleroderma
STUDY Pulsed High-Dose Corticosteroids Combined With Low-Dose Methotrexate in Severe Localized Scleroderma Alexander Kreuter, MD; Thilo Gambichler, MD; Frank Breuckmann, MD; Sebastian Rotterdam, MD; Marcus
More informationนพ.วาสนภ วช รมน หน วยโรคผ วหน ง คณะแพทยศาสตร โรงพยาบาลรามาธ บด
Vitiligo Vitiligo Update Acquired pigmentary disorder Depigmented macules and patches นพ.วาสนภ วช รมน หน วยโรคผ วหน ง คณะแพทยศาสตร โรงพยาบาลรามาธ บด Prevalence The prevalence of vitiligo is often said
More informationProject manager. Dr. Nicola Zerbinati. Therapeutic protocols of monochromatic source 355 nm λ
Project manager Therapeutic protocols of monochromatic source 355 nm λ INTRODUCTION Artificial ultraviolet rays (UV) such as sunbeds, lamps, solar panels, are used both in the beauty and medical field,
More informationVaginal involvement in genital erosive lichen planus
Acta Obstetricia et Gynecologica. 2010; 89: 966 970 SHORT REPORT Vaginal involvement in genital erosive lichen planus ANNE LISE ORDING HELGESEN 1,2,3, PETTER GJERSVIK 3,4, PETER JEBSEN 5, ROLF KIRSCHNER
More informationMedication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru493 Topic: Dupixent, dupilumab Date of Origin: March 10, 2017 Committee Approval: March 10, 2017
More informationRameshwar Gutte and Uday Khopkar
Extragenital unilateral lichen sclerosus et atrophicus in a child: a case report Rameshwar Gutte and Uday Khopkar Department of Dermatolgy, Seth GSMC and KEM Hospital, Parel, Mumbai-400012, India Egyptian
More informationBritish Association of Dermatologists guidelines for the management of lichen sclerosus 2018
British Association of Dermatologists guidelines for the management of lichen sclerosus 2018 WEB APPENDIX SUPPLEMENTARY INFORMATION Appendix A: Review Protocol Appendix B: Clinical Evidence summary Appendix
More informationA Retrospective Study on the Risk of Non-Melanoma Skin Cancer in PUVA and Narrowband UVB Treated Patients
Volume 1, Issue 3 Research Article A Retrospective Study on the Risk of Non-Melanoma Skin Cancer in PUVA and Narrowband UVB Treated Patients Darukarnphut P, Rattanakaemakorn P *, Rajatanavin N Division
More informationCitation for published version (APA): Coevorden, A. M. V. (2005). Hand eczema: clinical efficacy of interventions, and burden of disease s.n.
University of Groningen Hand eczema Coevorden, Anthony Marco van IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document
More informationNarrow band UVB (311 nm), psoralen UVB (311 nm) and PUVA therapy in the treatment of early-stage mycosis fungoides: a right left comparative study
Photodermatol Photoimmunol Photomed 2005; 21: 281 286 Blackwell Munksgaard Copyright r Blackwell Munksgaard 2005 Narrow band UVB (311 nm), psoralen UVB (311 nm) and therapy in the treatment of early-stage
More informationBath psoralen UVA photochemotherapy for localized scleroderma: experience from a single institute
Photodermatology, Photoimmunology & Photomedicine ORIGINAL ARTICLE Bath psoralen UVA photochemotherapy for localized scleroderma: experience from a single institute Felix Pavlotsky, Nicole Sakka, Alina
More informationThe use of CO2 laser for patients with Lichen sclerosus
The use of CO2 laser for patients with Lichen sclerosus Dr. Christina Kuhler-Obbarius, Elisabeth Kunkel, Dr. Matthias Theden-Schow, Hamburg, Germany Our clinical center located in Hamburg includes eight
More informationPsoriasis is a lifelong condition, with onset
THERAPEUTICS FOR THE CLINICIAN Clobetasol Propionate Lotion in the Treatment of Moderate to Severe Plaque-Type Psoriasis Jacques Decroix, MD; Henrik Pres, MD; Nicolaï Tsankov, MD; Michel Poncet, PhD; Stéphanie
More informationOriginal Policy Date
MP 2.01.07 Psoralens with Ultraviolet A (PUVA) Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed by consensus/12:2013 Return to Medical Policy
More informationDisorders of the vulva
Vulval lesions Disorders of the vulva Terminology standardised by the International Society for the Study of Vulvovaginal Disease(ISSVD) Classification 1.Nonneoplastic epithelial disorders of vulva Lichen
More informationA case of rosacea fulminans in a pregnant woman
Hong Kong J. Dermatol. Venereol. (2018) 26, 122-126 Views and Practice A case of rosacea fulminans in a pregnant woman JE Seol, SH Park, JU Kim, GJ Cho, SH Moon, H Kim Introduction Rosacea fulminans (RF)
More informationNational Managed Clinical Network For Phototherapy DOSIMETRY PROTOCOLS
National Managed Clinical Network For Phototherapy DOSIMETRY PROTOCOLS Photonet Dosimetry Protocols Revised March 2013 Review Date March 2015 1 MANAGED CLINICAL NETWORK SCOTLAND Photonet CONTENT DOSIMETRY
More informationEfficacy of Concomitant Use of PUVA and Methotrexate in Disease Clearance Time in Plaque Type Psoriasis
Efficacy of Concomitant Use of PUVA and Methotrexate in Disease Clearance Time in Plaque Type Psoriasis T. Shehzad ( Departments of Dermatology Naval Hospital PNS Shifa, Karachi. ) N. R. Dar ( Departments
More informationMaintenance Therapy of Adult Vitiligo with 0.1% Tacrolimus Ointment: A Randomized, Double Blind, Placebo Controlled Study
ORIGINAL ARTICLE Maintenance Therapy of Adult Vitiligo with 0.1% Tacrolimus Ointment: A Randomized, Double Blind, Placebo Controlled Study Marine Cavalié 1, Khaled Ezzedine 2, Eric Fontas 3, Henri Montaudié
More informationComparative efficacy of topical mometasone furoate 0.1% cream vs topical tacrolimus 0.03% ointment in the treatment of atopic dermatitis
Original Article Comparative efficacy of topical mometasone furoate 0.1% cream vs topical tacrolimus 0.03% ointment in the treatment of atopic dermatitis Md Alauddin Khan *, Lubna Khondker **, Dilshad
More informationA Vitiligo Update for Pharmacists: Current Practices and Future Advances
A Vitiligo Update for Pharmacists: Current Practices and Future Advances Dalal Hammoudi Halat, RPh, MSc, PhD Assistant Professor School of Pharmacy, Lebanese International University Disclosure Dalal Hammoudi
More informationCorporate Medical Policy
Corporate Medical Policy Ultraviolet Light Therapy in the Home Setting(UVB) File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ultraviolet_light_therapy_in_the_home 3/1996 11/2017 11/2018
More informationVulval dermatoses. Dr Fiona Lewis, Consultant Dermatologist St John s Institute of Dermatology, London & Heatherwood & Wexham Park Hospital, Slough
Vulval dermatoses Dr Fiona Lewis, Consultant Dermatologist St John s Institute of Dermatology, London & Heatherwood & Wexham Park Hospital, Slough Pigmentation Vulvodynia Ulcers Genetic Pruritus VULVAL
More informationOBSERVATION. Alexander Kreuter, MD; Christian Tigges, MD; Renata Gaifullina, MD; Julia Kirschke, MD; Peter Altmeyer, MD; Thilo Gambichler, MD
OBSERVATION Pulsed High-Dose Corticosteroids Combined With Low-Dose Methotrexate Treatment in Patients With Refractory Generalized Extragenital Lichen Sclerosus Alexander Kreuter, MD; Christian Tigges,
More informationCancer Association of South Africa (CANSA)
Cancer Association of South Africa (CANSA) Fact Sheet on the Use of Sunbeds Introduction A sunbed, also known as a tanning bed or sun tanning bed, is a device that emits ultraviolet radiation (typically
More informationLow-fluence Q-switched neodymium-doped yttrium aluminum garnet (1064nm) laser for the treatment of facial melasma in local population
Original Article Low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1064nm) laser for the treatment of facial melasma in local population Tahir Kamal, Usma Iftikhar* Department of Dermatology,
More informationSummary. DOI /j x
PHOTOBIOLOGY DOI 10.1111/j.1365-2133.2005.06533.x Comparison of the 308-nm excimer laser and a 308-nm excimer lamp with 311-nm narrowband ultraviolet B in the treatment of psoriasis K. Köllner, M.B. Wimmershoff,
More informationAn Efficacy Study of 3 Commercially Available Hydroquinone 4% Treatments for Melasma
An Efficacy Study of 3 Commercially Available Hydroquinone 4% Treatments for Melasma Pearl E. Grimes, MD Melasma is a common disorder of hyperpigmentation typically characterized by relatively symmetric
More informationA.HANNUKSELA-SVAHN, B.SIGURGEIRSSON,* E.PUKKALA,² B.LINDELOÈ F,³ B.BERNE, M.HANNUKSELA, K.POIKOLAINEN AND J.KARVONEN
British Journal of Dermatology 1999; 141: 497±501. Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and
More informationLichen sclerosus (LS) is an uncommon inflammatory. Constipation as a Feature of Anogenital Lichen Sclerosus in Children
Mandi L. Maronn, MD*, and Nancy B. Esterly, MD ABSTRACT. Objective. To call attention to constipation as a frequent sign of lichen sclerosus (LS) in girls. Methods. A focused questionnaire was sent to
More informationOCCG SERVICE SPECIFICATION (2017/18)
OCCG SERVICE SPECIFICATION (2017/18) Primary Care Service for Skin Cancers: Dermatology Shared Care Monitoring for Melanoma, Lichen Sclerosus and Squamos Cell Carcinoma 1. Background For patients who have
More informationLight Therapy for Psoriasis Protocol Medical Benefit Effective Date Next Review Date Preauthorization Review Dates Preauthorization is required.
Protocol Light Therapy for Psoriasis (20147) Medical Benefit Effective Date: 07/01/16 Next Review Date: 03/18 Preauthorization Yes Review Dates: 03/16, 03/17 Preauthorization is required. The following
More informationVitiligo is a skin depigmentation disorder
THERPEUTICS FOR THE CLINICIN Tacrolimus Ointment 0.1% Produces Repigmentation in Patients With Vitiligo: Results of a Prospective Patient Series Emil. Tanghetti, MD The cause of the selective melanocyte
More informationAssessing the Current Treatment of Atopic Dermatitis: Unmet Needs
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationVitiligo is an acquired cutaneous disorder of
Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo Lubomira Scherschun, MD, Jane J. Kim, MD, and Henry W. Lim, MD Detroit, Michigan Background: The treatment of vitiligo remains
More informationالاكزيماتيد= Eczematid
1 / 7 2 / 7 Pityriasis Debate confusing of hypopigmentation characterized increasing surrounded differ hypomelanotic "progressive exists alba misnomer extensive a to observed term the applied term derived
More informationLichen sclerosus is a chronic inflammatory
DERMATOLOGY Lichen Sclerosus et Atrophicus in a Young Girl YS Marfatia*, SoNIA JAIN** Abstract Lichen sclerosus et atrophicus is a chronic inflammatory dermatosis that results in white plaques and epidermal
More informationISPUB.COM. A Case of Actinic Lichen Planus. K Choi, H Kim, H Kim, Y Park INTRODUCTION CASE REPORT
ISPUB.COM The Internet Journal of Dermatology Volume 8 Number K Choi, H Kim, H Kim, Y Park Citation K Choi, H Kim, H Kim, Y Park.. The Internet Journal of Dermatology. 2009 Volume 8 Number. Abstract The
More informationPearls from the Mayo Clinic
Pearls from the Mayo Clinic Lawrence E. Gibson, MD Professor of Dermatology and Laboratory Medicine and Pathology Mayo Clinic College of Medicine Rochester, MN Tattoo infections Tattoos very common (>24%
More informationUpdate on emollients
Update on emollients Amal Mhanna, MD Pediatric Dermatologist Clemenceau Medical Center Disclosure: I was a member of an advisory board y for J&J and received honoraria. Emollients and moisturizers are
More informationSTUDY. A Randomized Comparison of Methods of Selecting Narrowband UV-B Starting Dose to Treat Chronic Psoriasis
ONLINE FIRST STUDY A Randomized Comparison of Methods of Selecting Narrowband UV-B Starting Dose to Treat Chronic Psoriasis Robert S. Dawe, MBChB, MD, FRCP; Heather M. Cameron, MBChB, MRCGP; Susan Yule,
More informationCHAPTER 2. Is severity eruption assessment possible? in polymorphous light
CHAPTER 2 Is severity assessment in polymorphous light Is severity eruption assessment possible? in polymorphous light Ines Schornagel, eruption Kees Guikers, possible? Huib van Weelden, Carla Bruijnzeel-Koomen
More informationCorporate Medical Policy
Corporate Medical Policy Light Therapy for Dermatologic Conditions File Name: Origination: Last CAP Review: Next CAP Review: Last Review: light_therapy_for_dermatologic_conditions 5/2012 11/2017 11/2018
More informationTopical interventions for genital lichen sclerosus (Review)
Chi CC, Kirtschig G, Baldo M, Brackenbury F, Lewis F, Wojnarowska F This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2011,
More informationClinical Policy: Phototherapy and Photochemotherapy for Dermatological Conditions Reference Number: CP.MP. 441
Clinical Policy: Phototherapy and Photochemotherapy for Dermatological Conditions Reference Number: CP.MP. 441 Effective Date: November 2008 Last Review Date: January 2017 See Important Reminder at the
More informationEFFICACY AND SAFETY OF CLOBETASOL PROPIONATE SHAMPOO IN THERAPY OF PSORIASIS OF THE SCALP
WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Platonova et al. SJIF Impact Factor 2.786 Volume 4, Issue 04, 238-246. Research Article ISSN 2278 4357 EFFICACY AND SAFETY OF CLOBETASOL PROPIONATE
More informationJAM ACAD DERMATOL VOLUME 76, NUMBER 2. Research Letters 351
JAM ACAD DERMATOL Research Letters 351 Standard step sectioning of skin biopsy specimens diagnosed as superficial basal cell carcinoma frequently yields deeper and more aggressive subtypes To the Editor:
More informationTopical betamethasone for the prevention of acute radiation dermatitis in breast cancer patients
Iran. J. Radiat. Res., 23; (2): 5 - Topical betamethasone for the prevention of acute radiation dermatitis in breast cancer patients F. Farhan, A. Kazemian, H. Alagheband Radiotherapy-Oncology Department,
More informationIndex. derm.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A AA. See Alopecia areata. Acrofacial vitiligo presentation of, 135, 136 AD. See Atopic dermatitis. Adaptive immunity and vitiligo, 258
More information2 SYNOPSIS. Study code : MC 9308 FR.
MC9308 FR Study 19 December 2000 Page 15 of142 2 SYNOPSIS Study code : MC 9308 FR. Title: A comparative study of calcipotriol ointment in combination with narrow-band UVB (TL-01) phototherapy and placebo
More informationPrescribing Information
Prescribing Information Pr DERMOVATE Cream (clobetasol propionate cream, USP) Pr DERMOVATE Ointment (clobetasol propionate ointment, USP) Topical corticosteroid TaroPharma Preparation Date: A Division
More informationSPECIAL TOPIC. Institut National de la Sante et de la Recherche Medicale (INSERM U895), Nice, France c
November 2011 1260 Volume 10 Issue 1i Copyright 2011 ORIGINAL ARTICLES Journal of Drugs in Dermatology SPECIAL TOPIC A Pilot Study Using Reflectance Confocal Microscopy (RCM) in the Assessment of a Novel
More informationGunasundari October 15, :57 PM 13:57 4 Color Fig(s):0 Art: GOX-D
Original Article Reconstructive Use of Platelet-rich Plasma for Vulvovaginal Autoimmune Conditions Like Lichen Sclerosus AQ1 AQ2 Fariba Behnia-Willison, MBBS, MIS, FRANZCOG* Nina R. Pour, O&G SRMO-DRANZCOG
More informationLichen Sclerosus. Exceptional healthcare, personally delivered
Lichen Sclerosus Exceptional healthcare, personally delivered Lichen Sclerosus (LS) is an itchy skin condition usually affecting genital skin, but it can occur elsewhere. It affects women more often than
More informationPhotochemotherapy MM /09/2004. HMO; PPO; QUEST Integration June 1, 2016 Section: Medicine Place(s) of Service: Home; Office
Photochemotherapy Policy Number: Original Effective Date: MM.02.015 11/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration June 1, 2016 Section: Medicine Place(s) of Service:
More informationScottish Medicines Consortium
Scottish Medicines Consortium ustekinumab, 45mg solution for injection (Stelara ) No. (572/09) Janssen-Cilag Ltd 15 January 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of
More informationPhotochemotherapy MM /09/2004. HMO; PPO; QUEST Integration 08/25/2017 Section: Medicine Place(s) of Service: Home; Office
Photochemotherapy Policy Number: Original Effective Date: MM.02.015 11/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 08/25/2017 Section: Medicine Place(s) of Service:
More informationClinical Study Polydeoxyribonucleotide Dermal Infiltration in Male Genital Lichen Sclerosus: Adjuvant Effects during Topical Therapy
Dermatology Research and Practice Volume 213, Article ID 65479, 7 pages http://dx.doi.org/1.1155/213/65479 Clinical Study Polydeoxyribonucleotide Dermal Infiltration in Male Genital Lichen Sclerosus: Adjuvant
More informationIMO 3100, an antagonist of Toll like receptor (TLR) 7 and TLR9, demonstrates clinical activity in psoriasis patients
IMO 3100, an antagonist of Toll like receptor (TLR) 7 and TLR9, demonstrates clinical activity in psoriasis patients with 4 weeks of treatment in a Phase 2a trial A. B. Kimball 1, J. Krueger 2, T. Sullivan
More informationClinical Study Report Synopsis
Clinical Study Report Synopsis An Explorative Clinical Trial to Evaluate an Intra Patient Comparison Design of Topical Agents in Adults with Mild to Moderate Atopic Dermatitis Design of trial: Single-centre,
More informationTopical Immunomodulator Step Therapy Program
Topical Immunomodulator Step Therapy Program Policy Number: 5.01.557 Last Review: 8/2017 Origination: 7/2013 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) BCBSKC will provide
More informationPhototherapy for Psoriasis. Henry W. Lim, MD Chairman and C.S. Livingood Chair Department of Dermatology Henry Ford Hospital, Detroit, MI, USA
Phototherapy for Psoriasis Henry W. Lim, MD Chairman and C.S. Livingood Chair Department of Dermatology Henry Ford Hospital, Detroit, MI, USA Disclosure Investigator: Clinuvel Estée Lauder Ferndale Incyte
More informationTHE EFFECTS OF REPEATED SUB-ERYTHEMAL EXPOSURES OF UVR ON HUMAN IMMUNITY
THE EFFECTS OF REPEATED SUB-ERYTHEMAL EXPOSURES OF UVR ON HUMAN IMMUNITY Joanna Narbutt Department of Dermatology Medical University of Lodz, Lodz, Poland Photoimmunosuppression ULTRAVIOLET RADIATION DNA
More informationPHOTOTHERAPY. With narrowband UVB, the light tubes produce a narrow part of the UVB spectrum. Two wavelengths
Phototherapy (light therapy) refers to the use of ultraviolet (UV) light to treat moderate to severe eczema in children and adults. Phototherapy is a second-line treatment option that is available at specialist
More information308-nm excimer laser plus topical calcipotriol in the treatment of vitiligo; A single blind randomized clinical study
Original Article 308-nm excimer laser plus topical calcipotriol in the treatment of vitiligo; A single blind randomized clinical study Hassan Seirafi, MD 1 Maryam Daneshpazhouh, MD 1 Somayeh Khezri, MD
More informationAn Update on Topical Therapy for Atopic Dermatitis
An Update on Topical Therapy for Atopic Dermatitis Amy S. Paller, M.D. Professor and Chair of Dermatology Professor of Pediatrics Northwestern University Feinberg School of Medicine Chicago, Illinois Disclosures
More informationEffectiveness of treating non-specific pruritus vulvae with topical steroids: A randomized controlled trial
European Journal of General Practice. 2009; 15: 2933 ORIGINAL ARTICLE Effectiveness of treating non-specific pruritus vulvae with topical steroids: A randomized controlled trial ANTOINE L. M. LAGRO-JANSSEN
More informationTreatment of Bowenoid and Basaloid Vulvar Intraepithelial Neoplasia 2/3 with Imiquimod 5% Cream DO NOT DUPLICATE
The Journal of Reproductive Medicine Treatment of Bowenoid and Basaloid Vulvar Intraepithelial Neoplasia 2/3 with Imiquimod 5% Cream Claudia Marchitelli, M.D., Graciela Secco, M.D., Myriam Perrotta, M.D.,
More informationA Comparison of the Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy according to the Density of Ablative Laser Channel
A Comparison of the Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy according to the Density of Ablative Laser Channel in the Treatment of Actinic Keratosis Yeo-Rye Cho, Jeong-Hwan
More informationNews in erosive lichen planus of the vulva
News in erosive lichen planus of the vulva Anne Lise Helgesen Dermatologist, Postdoc, National Centre of Womens Health, Oslo University Hospital, Oslo, Norway - a great challenge WHY? No evidence based
More informationOsteopathic Dermatology
Osteopathic Dermatology Teodor Huzij, DO, FACN Reagan Anderson, DO, FAOCD, FASMS, Certificate of Added Qualification for Mohs Surgery, MPH, MCS, Program Director for RVU/CDI Dermatology Residency Program
More informationFor thousands of years, sunlight has been used to treat a
Phototherapy in the Age of Biologics Daniel Walker, BS, and Heidi Jacobe, MD, MSCS Dermatologists are presented with a diversity of therapeutic modalities for the treatment of inflammatory, sclerosing,
More informationPravit Asawanonda, MD, DSc, and Yaowalak Nateetongrungsak, MD Bangkok, Thailand
Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: A randomized, placebo-controlled study Pravit Asawanonda, MD, DSc, and
More informationCitation The Journal of Dermatology, 37(8), available at
NAOSITE: Nagasaki University's Ac Title Two cases of blaschkitis with promi Author(s) Utani, Atsushi Citation The Journal of Dermatology, 37(8), Issue Date 2010-08 URL Right http://hdl.handle.net/10069/25634
More informationSCIENTIFIC PAPER ABSTRACT
SCIENTIFIC PAPER ABSTRACT Vitiligo Treatment with Monochromatic Excimer Light and Tacrolimus: Results of an Open Randomized Controlled Study Nistico` S., Chiricozzi A., M.D., Rosita Saraceno R., Schipani
More informationActinic keratosis (AK): Dr Sarma s simple guide
Actinic keratosis (AK): Dr Sarma s simple guide Actinic keratosis is a very common lesion that you will see in your day-to-day practice. First, let me explain the name Actinic keratosis. It means keratosis
More informationKey words: genotyping/hla-dq/hla-dr/lichen sclerosus/susceptibility J Invest Dermatol 125: , 2005
The Association Between HLA DR, DQ Antigens, and Vulval Lichen Sclerosus in the UK: HLA DRB1 12 and its Associated DRB1 12/DQB1 0301/04/09/010 Haplotype Confers Susceptibility to Vulval Lichen Sclerosus,
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2116-3 Program Prior Authorization/Medical Necessity Medications Dupixent (dupilumab) P&T Approval Date 1/2017, 5/2017, 7/2017
More informationOriginal article Comparative study of psoralen-uvb vs. UVB-alone therapy in the treatment of psoriasis
Original article Comparative study of psoralen-uvb vs. UVB-alone therapy in the treatment of psoriasis Syed Shamsuddin, *Tahir Saeed Haroon Department of Dermatology, Bolan Medical Complex, Quetta * Department
More informationMALE GENITAL (PENIS) LICHEN SCLEROSUS
MALE GENITAL (PENIS) LICHEN SCLEROSUS What are the aims of this leaflet? This leaflet has been written to help you understand more about male genital lichen sclerosus (also known as balanitis xerotica
More informationFollow this and additional works at: Part of the Skin and Connective Tissue Diseases Commons
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2016 Is Narrowband UVB Phototherapy in Combination
More informationTherapeutic Management of Early Cutaneous Mycosis Fungoides
Therapeutic Management of Early Cutaneous Mycosis Fungoides L Frank Glass, MD Cutaneous Lymphoma Programs H Lee Moffitt Cancer Center and Research Institute George Washington University Dermatology and
More informationAssessing and Treating the Patient with Chronic Itch
Assessing and Treating the Patient with Chronic Itch Sonja Ständer, MD sonja.stander@uni-muenster.de Center for Chronic Pruritus Department of Dermatology University Hospital of Muenster Germany Acute
More informationPsoriasis is a chronic, inflammatory, T-cell mediated
Narrowband UVB Treatment Increases Serum 25-Hydroxyvitamin D Levels in Patients With Chronic Plaque Psoriasis Seyamak Saleky, MD; Işıl Bulur, MD; Zeynep Nurhan Saraçoğlu, MD PRACTICE POINTS The 25-hydroxyvitamin
More information